HISUN(SH:600267) Zheng Quan Zhi Xing·2025-08-25 17:05Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. held its sixth meeting of the tenth board of directors on August 22, 2025, where several key resolutions were passed, including asset impairment provisions, correction of prior accounting errors, and governance structure adjustments [1][2][3]. Group 1: Financial Decisions - The board approved the proposal for asset impairment provisions with unanimous support [1]. - A resolution was passed to correct prior accounting errors, also receiving unanimous approval [2]. - The half-year report for 2025 was reviewed and approved by the board [2]. Group 2: Governance Changes - The company decided to abolish the supervisory board and amend its articles of association to enhance governance structure, with the audit committee taking over relevant responsibilities [2][3]. - The proposal to establish, amend, and abolish certain corporate governance systems was approved, aimed at improving operational standards [4]. Group 3: Strategic Initiatives - The company plans to publicly transfer 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., with an estimated value of 392.23 million yuan and a proposed minimum transfer price of 430 million yuan [4][5]. - A resolution was passed to establish a wholly-owned subsidiary in Brazil, with an investment of 5 million Brazilian Reais, to support international expansion [5][6]. Group 4: Social Responsibility - The company and its subsidiaries will donate medicines valued at approximately 2.14 million yuan to the Xinjiang Red Cross Foundation, reflecting its commitment to social responsibility [6]. Group 5: Upcoming Events - The company has scheduled its first extraordinary general meeting of 2025 for September 10, 2025, to discuss the resolutions passed [7].